Eli Lilly said last night it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation ...

When hospitals overcharge insurers for drugs they bought at deep 340B discounts, taxpayers, employers, and insured patients ...

With post-pandemic Medicaid enrollments on the decline and expected to fall further, revenue cycle leaders warn that ...

The 340B Drug Pricing Program is under pressure from multiple directions: pharmacy benefit manager litigation, drugmaker contract pharmacy restrictions, and a federal rebate pilot that courts have ...

Drug manufacturers participating in the Section 340B Drug Pricing Program now face a significant new litigation risk under the False Claims Act (“FCA”). In a recent decision, Adventist Health System v ...

Effective compliance now spans transaction eligibility, OPAIS synchronization, Medicaid exclusion validation, cost-report ...

The 340B program is criticized for generating revenue rather than solely aiding underinsured patients, impacting community providers and Medicare patients. Pharmaceutical companies face challenges ...

Minnesota's 340B drug discount program faces scrutiny as small clinics struggle and large hospitals profit, sparking ...

Nevada hospitals and clinics face challenges as drug manufacturers restrict access to a federal discount drug program, ...

Pending legislation to expand providers’ access to discounted drugs has sparked strong lobbying campaigns for and against the ...